Genetics and Genomics | Open Access | Published:

Genetics & Genomics

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

British Journal of Cancer volume 103, pages 581589 (10 August 2010) | Download Citation

This article has been updated



The impact of thymidylate synthase (TYMS) and UDP-glucoronosyltransferase 1A (UGT1A) germline polymorphisms on the outcome of colorectal cancer (CRC) patients treated with irinotecan plus 5-fluorouracil (irinotecan/5FU) is still controversial. Our objective was to define a genetic-based algorithm to select patients to be treated with irinotecan/5FU.


Genotyping of TYMS (5′TRP and 3′UTR), UGT1A1*28, UGT1A9*22 and UGT1A7*3 was performed in 149 metastatic CRC patients treated with irinotecan/5FU as first-line chemotherapy enrolled in a randomised phase 3 study. Their association with response, toxicity and survival was investigated by univariate and multivariate statistical analysis.


TYMS 3TRP/3TRP genotype was the only independent predictor of tumour response (OR=5.87, 95% confidence interval (CI)=1.68–20.45; P=0.005). UGT1A1*28/*28 was predictive for haematologic toxicity (OR=6.27, 95% CI=1.09–36.12; P=0.04), specifically for neutropenia alone (OR=6.40, 95% CI=1.11–37.03; P=0.038) or together with diarrhoea (OR=18.87, 95% CI=2.14–166.67; P=0.008). UGT1A9*1/*1 was associated with non-haematologic toxicity (OR=2.70, 95% CI=1.07–6.82; P=0.035). Haplotype VII (all non-favourable alleles) was associated with non-haematologic toxicity (OR=2.11, 95% CI=1.12–3.98; P=0.02).


TYMS and UGT1A polymorphisms influence on tumour response and toxicities derived from irinotecan/5FU treatment in CRC patients. A genetic-based algorithm to optimise treatment individualisation is proposed.


Despite the development of novel anticancer agents, such as bevacizumab, cetuximab or panitumumab, the backbone of metastatic colorectal cancer (CRC) treatment is based on the combination of 5-fluorouracil (5FU) (±leucovorin), oxaliplatin and irinotecan (O'Neil and Goldberg, 2008). For first-line treatment, oxaliplatin+5FU or irinotecan+5FU are indistinctly used. With regard to irinotecan-based schedules, about 50% of patients respond to therapy but half of them are expected to experience some kind of severe toxicity, mainly diarrhoea and neutropenia, resulting either in dose reduction, treatment withdrawal or dying (Slichenmyer et al, 1994; Douillard et al, 2000). The significant patient variability in response and toxicity and the existence of common genetic variants within genes important to their metabolism and/or activity, highlights the relevance of pharmacogenetic studies that could help to identify individuals with a higher probability of developing severe toxicity or an increased response rate. The efficacy of irinotecan depends on activation by carboxyesterases to form the active metabolite SN38 (Kawato et al, 1991; Sanghani et al, 2003). To facilitate its elimination, SN38 is glucoronidated by UDP-glucoronosyltransferase 1A (UGT1A) enzymes, mainly by the hepatic UGT1A1 but also by UGT1A7 and UGT1A9 (Ciotti et al, 1999; Gagne et al, 2002). Genetic variation in UGT1A1 enzyme was first related to the Gilbert's syndrome, in which the homozygous variant genotype UGT1A1*28/*28 is responsible for a less efficient bilirrubin glucoronidation (Monaghan et al, 1996). Later, a series of publications demonstrated that genotyping of UGT1A1*28 could also serve to predict irinotecan-associated severe toxicity. Thus, in 2005, the US Food and Drug Administration suggested that patients homozygous for UGT1A1*28 should receive a reduced starting dose of irinotecan by at least one level. However, given that the UGT1A1*28/*28 genotype does not explain many cases of severe toxicity, other factors, genetic and nongenetic, should be analysed. Results from several studies have shown that other genetic variants within the UGT1A1 sequence and also in UGT1A7 and UGT1A9 isoforms have to be taken into account (Carlini et al, 2005; Han et al, 2006; Cecchin et al, 2009). Moreover, Thymidylate synthase (TYMS) polymorphisms located in 5′UTR region are, probably, of the most broadly studied genetic variants in the field of pharmacogenetics in CRC (Marsh, 2005). It is quite accepted that the 3TRP allele is associated with increased levels of the chemotherapeutic target TYMS (mRNA, protein or activity depending on the different studies) (Kawakami et al, 2001; Etienne et al, 2002; Ishida et al, 2002) and this fact has been associated with poorer outcome in patients treated with 5FU-based regimens both in the adjuvant and in the metastatic setting (Iacopetta et al, 2001; Pullarkat et al, 2001). Also, the 6 bp deletion in the 3′UTR of TYMS gene has been correlated with increased message instability and consequently, lower levels of TYMS mRNA (Mandola et al, 2004).

The aim of this study was to elucidate which UGT1A polymorphisms or combination of them should be analysed to better predict severe toxicity in colorectal patients treated with irinotecan-based first-line chemotherapy. We also studied the influence of their haplotypes and of TYMS variants.

Materials and methods

Study design and patients

A representative sample (N=149, 43%) of patients from a multicentre, prospective, randomised phase III study (N=346) in first-line CRC treatment, carried out by the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD Group), was included in this analysis. Patients were selected based on availability of blood samples. The study compared weekly irinotecan (80 mg m−2) plus high-dose 5FU (FUIRI) vs biweekly irinotecan (180 mg m−2) plus 5FU/LV (FOLFIRI) as first-line chemotherapy for patients with metastatic CRC. The conclusions of the trial and details on eligibility criteria, treatment schedules, guidelines for dose-modifications and all the study details have already been published. In summary, FUIRI represented a less complex and equivalent alternative to the standard FOLFIRI regimen (Aranda et al, 2009). Median follow-up of the study was 17.2 months (95% confidence interval (CI)=15.7–18.5). Toxicities were grouped as haematologic (neutropenia, leucopenia, thrombocytopenia and anaemia) or non-haematologic (diarrhoea, nausea, vomiting, asthenia, anorexia, mucositis and non-neutropenic infection). Grade 3–4 toxicity was considered as severe. The pharmacogenetic study protocol was approved by the local ethics committee, and all subjects gave informed consent before participating in the study.

Genetic analyses

Genotypes were determined in DNA extracted from peripheral blood samples using the QiAmp DNA Blood Mini kit (Qiagen, Valencia, CA, USA) according to manufacturer's instructions. The TS promoter region polymorphism (5′VNTR) was analysed through standard PCR method and the 3′UTR polymorphism was analysed by GeneScan, both as previously described (Martinez-Balibrea et al, 2008). UGT1A1*28 and UGT1A9*22 were analysed by automatic sequencing using forward (5′-CTGAAAGTGAACTCCCTGCTACCT-3′ and 5′-GCTTCTAAACTTAACATTGCAGCACA-3′, respectively) and reverse (5′-GCAGGAGCAAAGGCGCCATG-3′ and 5′-CTGGGAATCTAAGCTCCTATGATACA-3′, respectively) nested primers with an ABI Prism 3100 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). To define UGT1A7*1, UGT1A7*2, UGT1A7*3 and UGT1A7*4 alleles, we performed an allelic discrimination assay in an ABI Prism 7000 system (Applied Biosystems) for UGT1A7 N129K R131K and W208R variants (Guillemette et al, 2000). A graphic representation of these polymorphic sites can be found in Figure 1. As a control, we also performed an allelic discrimination assay for UGT1A7-57 (T → G), which is completely linked to UGT1A7 W208R (Lankisch et al, 2005). We used primers and probes already reported (Lankisch et al, 2005). All primers and probes were designed and/or validated by using the Primer Express software v2.0 from Applied Biosystems.

Figure 1
Figure 1

Graphic representation of three of the polymorphic sites (codons 129, 131 and 208) studied on the human UGT1A7 exon 1 sequence. The corresponding alleles are shown. Changes in base pairs are shown in bold, whereas changes in amino-acid sequence are shown in italics.


In this retrospective analysis within a prospective trial, we evaluated the association between UGT1A genotypes/haplotypes and TYMS genotypes and toxicity (severe toxicity at first cycle and at the end of treatment), response rate, time to progression (TTP) and overall survival (OS). Each polymorphism was tested to ensure that it fitted Hardy–Weinberg equilibrium. The associations between categorical variables were assessed by χ2-tests or Fisher's exact test whenever required. Also, logistic regression models were used to estimate the associations of genotypes and toxicity or response to treatment. Each polymorphism was analysed as a three-group categorical variable (codominant model), and also other restricted inheritance models were used (log-additive, dominant and recessive). Linkage disequilibrium (LD) between polymorphisms was calculated and the analysis of inferred haplotypes was also performed. The web tool SNPstats (Sole et al, 2006) was used for the genetic analyses and some analyses were also performed in R ( The Kaplan–Meyer plots were used to estimate TTP and OS curves. The association of genetic variants and clinical parameters with TTP and OS was assessed with the log-rank test, and also hazard ratios (HR) and their 95% CIs were estimated from univariate and multivariate Cox proportional hazards regression models. In general, differences were considered statistically significant when two-sided P-values were <0.05. However, to account for multiple comparisons when analysing polymorphisms or haplotypes, a Bonferroni correction was applied and significant differences were considered for P-values <0.005. This assumes 10 independent comparisons and should suffice for a nominal 0.05 type I error protection for five independent SNPs that were analysed in several correlated inheritance models and haplotypes.


Allelic, genotypic and haplotypic frequencies and LD analysis

Allelic and genotypic frequencies were calculated for all genetic variants and are shown in Table 1. All variants were in Hardy–Weinberg equilibrium. As previously reported (Lurje et al, 2008), TS 5′TRP and TS 3′UTR polymorphism were in LD (D′=0.538; r2=0.1) but no linkage was observed between these and UGT1A variants (Figure 2). UGT1A7 W208R and UGT1A7-57 variants were totally linked as described before (Lankisch et al, 2005) (D′=1.00; r2=1.00) and a high LD was observed between them and UGT1A7 N129K variant (D′=0.99; r2=0.427). UGT1A9 and UGT1A7 variants were more linked to each other (0.922<D′<1.00; 0.381<r2<0.958) than to UGT1A1*28 (0.661<D′<0.76; 0.167<r2<0.494) (Figure 2). UGT1A haplotypes I, II, III and VII were in a frequency >5% and therefore they were considered in response, toxicity and survival analysis. Haplotype VII harbours all UGT1A variants previously associated with severe toxicity (UGT1A1*28, UGT1A9*1 and UGT1A7*3) (Table 1).

Table 1: (I) Genotype and allele frequencies for all polymorphisms, (II) UGT1A haplotypes
Figure 2
Figure 2

Pairwise linkage disequilibrium relationships between TYMS and UGT1A variants. The Lewontin's coefficient D′ and the correlation coefficient r2 are reported. A grey scale represents statistical significance of the association.

Response to therapy

A total of 147 patients were evaluable for response. The majority of them (47.7%) attained a partial response or tumour stabilisation (34.9%), whereas 5.4% had a tumour progression and 10.7% a complete response. These response rates were similar to those obtained in the whole study (Aranda et al, 2009). Patients were grouped as responders (R, 58.4%) if they had a partial or a complete response, or as no responders (NR, 41.6%) if they had a tumour stabilisation or progression. Seventy four percent of patients received more than three cycles of chemotherapy. Among all clinical variables, poor tumour differentiation and number of chemotherapy cycles received 3 were negatively associated with tumour response (P=0.023 and 0.038, respectively). Patients whose primary tumour was located in the rectum were more likely to respond to chemotherapy (64.1 vs 49.1% for colon tumours), although these differences were not statistically significant (P=0.076). All results for the association of clinical variables and response to therapy are shown in Table 2. When genetic variants were taken into account, only TS 5′TRP polymorphism was strongly associated with response to therapy. As shown in Table 3, 79% of patients harbouring the 2TRP/2TRP genotype responded to therapy, whereas 61 and 40% of patients heterozygous and homozygous for the 3TRP allele, respectively, did so (P=0.0024). None of the UGT1A variants or haplotypes was associated with response to therapy. In the multivariate analysis, TS 5′TRP genotype, grade of tumour differentiation and number of chemotherapy cycles were independent predictive factors of response (Table 4).

Table 2: Clinical features, response and toxicity
Table 3: Genotypes, haplotypes and response to treatment
Table 4: Logistic regression analysis


The most frequent severe toxicities were as follows: diarrhoea (30.2%), neutropenia (20.8%), vomiting (5.37%), mucositis (4.03%), nausea (2.68%), leucopenia (2.01%), febrile neutropenia (1.34%) and thrombocytopenia (0.67%). Patients who received FOLFIRI had greater rates of severe neutropenia (30 vs 11%), whereas patients who received FUIRI had greater rates of severe diarrhoea (40 vs 18%). Although in this cohort there were no treatment-related deaths (there were 6 treatment-related deaths in the global study), 10 patients (6.7%) experienced severe neutropenia and diarrhoea at the same time. To make the genetic analysis more comprehensive, we analysed those genotypes previously associated with severe toxicities (i.e., UGT1A1*28/*28, UGT1A9*1/*1 and UGT1A7*3/*3) vs the rest of the genotypes for a given polymorphism (e.g., UGT1A1*28/*28 vs UGT1A1*28/*1 and UGT1A1*1/*1). The detailed analysis can be found in the Supplementary Table S1 (online only). Given that the occurrence of diarrhoea and neutropenia at the same time is considered as a life-threatening irinotecan-related toxicity, we also studied its relationship with all the UGT1A variants. At the end of the first cycle of treatment, patients harbouring either the UGT1A1*28/*28, all or some non-favourable UGT1A genotypes (either UGT1A1*28/*28 or UGT1A7*3/*3 or UGT1A9*1/*1), or the haplotype VII were at a higher risk of developing non-haematologic toxicity. Patients with UGT1A1*28/*28 or some unfavourable UGT1A genotype had higher rates of severe diarrhoea (Table 5). At the end of treatment, UGT1A1*28/*28 and all non-favourable genotypes were associated with haematologic and non-haematologic toxicities, severe neutropenia and diarrhoea and both. Patients with the UGT1A9*1/*1 genotype were more likely to develop severe non-haematologic toxicity and diarrhoea, whereas UGT1A7*3/*3 genotype was also associated with the occurrence of neutropenia and diarrhoea simultaneously. Patients harbouring some of the unfavourable genotypes or the haplotype VII were at a higher risk of developing non haematologic toxicity and severe diarrhoea (Table 5). In a multivariate logistic regression analysis, UGT1A1*28/*28 genotype was an independent predictive factor of haematologic toxicity and severe neutropenia with or without diarrhoea at the end of treatment. At the end of the first cycle of chemotherapy, this genotype predicted for severe diarrhoea and non-haematologic toxicity (Table 4). UGT1A9*1/*1 genotype and age older than 65 years were independent predictive factors of non-haematologic toxicity at the end of treatment. UGT1A9*1/*1 and UGT1A7*3/*3 were associated with higher risk of severe diarrhoea at the end of the first cycle of chemotherapy (Table 4). It is worth highlighting that those patients with TS 2TRP/2TRP that harboured some non-favourable UGT1A genotype were more likely to develop severe toxicity at the end of the first cycle of chemotherapy and at the end of treatment (46 vs 6%; χ2 P=0.018 and 64 vs 28%; χ2 P=0.12). We did not observe any association between TYMS genotypes and toxicity (data not shown).

Table 5: UGT1A genotypes, haplotypes and toxicity


Median TTP and OS were 9.2 months (95% CI=8.4–10.0) and 24.3 months (95% CI=21.8–26.8), respectively. There was no statistical association between any of the genotypes, UGT1A haplotypes or clinical variables and TTP or OS (data not shown). However, patients homozygous for the 2TRP allele had a median OS of 27.3 months (95% CI=23.9–30.7), whereas patients homozygous for the 3TRP allele had a median OS of 21.4 months (95% CI: 19.1–23.7) (HR=1.59; 95% CI: 0.91–2.76; log-rank P=0.14). Heterozygous patients had a median OS similar to that of the whole group (24.3 months; 95% CI=19.5–29.2). Interestingly, those patients within the group 2TRP/2TRP with some non-favourable UGT1A genotype had longer OS times (34.5 vs 25.3 months, log-rank P=0.13) (Figure 3).

Figure 3
Figure 3

Overall survival curves of patients with some non-favourable (UGT1A1*28/*28 or UGT1A7*3/*3 or UGT1A9*1/*1) UGT1A genotype (solid line) or with all favourable UGT1A genotypes (dotted line). Reported P-value corresponds to the log-rank test.


The usefulness of genetic testing to predict irinotecan-related toxicities has been widely discussed, but still not clearly convincing as indicated from recent works by Cecchin et al (2009) and Braun et al (2009). This study helps in identifying those CRC patients with a high risk of developing life-threatening toxicities (i.e., severe neutropenia and diarrhoea) when treated with irinotecan plus 5FU regimens. Our data confirm the role of UGT1A1*28 variant as the most important in taking a decision and, for the first time, reveals TYMS 5′TRP polymorphism to be strongly related with tumour response in these patients. Furthermore, this is the third of the largest studies evaluating different UGT1A polymorphisms in Caucasians (Cote et al, 2007; Cecchin et al, 2009). Owing to the retrospective nature of the study, pharmacokinetic analysis could not be performed, being this fact a weak point of this study.

Among all UGT1A variants studied, UGT1A1*28 was the most widely correlated with severe toxicity in the multivariate analysis (see Table 4). It is noteworthy that 33.3% of patients homozygous for the UGT1A1*28 allele developed severe neutropenia and diarrhoea at the same time, whereas only 1.8% of UGT1A1*1/*1 and 5.2% of UGT1A1*1/*28 patients did so (OR=12.38, 95% CI=2.38–54.18, P<0.0001, Supplementary Table S1). Taking into account the high risk of dying of these patients, it has to be considered either not to treat them with irinotecan-containing regimens or to give them a reduced starting dose of irinotecan. UGT1A1*28 was specifically associated with neutropenia at the end of treatment and with diarrhoea after first cycle of chemotherapy. Patients homozygous for the UGT1A1*28 allele were at a higher risk of developing any kind of severe toxicity at the end of treatment and severe non-haematologic toxicity (specifically diarrhoea) at the end of the first cycle of chemotherapy (Table 5). Our results are somehow in agreement with the majority of the published studies (Marcuello et al, 2004; Cote et al, 2007; Ruzzo et al, 2008; Cecchin et al, 2009).

We chose to study UGT1A1*28, UGT1A7*3 and UGT1A9*22 variants based on their functional significance (Iyer et al, 1998, 1999; Guillemette et al, 2000; Gagne et al, 2002; Lankisch et al, 2005). It has been suggested that the UGT1A1*93 variant might be a better predictor of the UGT1A1 status than the UGT1A1*28 (Innocenti et al, 2004), but based on two recent studies from the same group (Cecchin et al, 2009; Innocenti et al, 2009) this possibility remains to be proven. Also it is worth highlighting that the functional significance of this variant is still unknown.

It has been suggested that the effect of UGT1A1*28 on haematologic irinotecan-related toxicity is weaker when the drug is administered at intermediate doses (<250 mg m−2) (Hoskins et al, 2007). Our results do not support this observation given that patients in our study received either 80 mg m−2 weekly or 180 mg m−2 biweekly of irinotecan and the association with toxicity was strong. Thus, our data should be taken into account together with those from other authors (Marcuello et al, 2004; Rouits et al, 2004).

UGT1A7*3 and UGT1A9*22 variants had a minor impact on toxicity and cannot be excluded that the apparent effect could be due to LD with UGT1A1*28. Nevertheless, in the multivariate analysis, patients with UGT1A7*3/*3 and UGT1A9*1/*1 genotypes were more likely to develop diarrhoea after first cycle of chemotherapy (Table 4). Our results are in agreement with those of Han et al (2006). These authors reported an association between these variants and lower area under the time-concentration curve SN-38G to SN-38 ratio. UGT1A9*1/*1 showed a trend for high incidence of severe diarrhoea (Han et al, 2006). In another study, these variants were associated with haematologic toxicity (Cecchin et al, 2009).

We hypothesised that harbouring one of these variants would increase the risk of developing treatment-related toxicities. Our hypothesis was confirmed by haplotype and combined genotype analysis. Thus, 7% of patients had all unfavourable genotypes and they experienced higher rates of all severe toxicities at the end of treatment and non-haematologic (specifically diarrhoea) toxicity at the end of the first cycle of chemotherapy (Table 5). Haplotype VII that contains all toxicity-related alleles (UGT1A1*28, UGT1A7*3 and UGT1A9*1) was associated with non-haematologic toxicity both at the end of first cycle and at the end of treatment (Table 5).

Unlike Han et al (2006) and Cecchin et al (2009) but in agreement with Liu et al (2008), we did not find an association of UGT1A genetic variants with either response, TTP or OS.

Interestingly, a strong correlation between TYMS 5′TRP genotypes and response to treatment was observed in our study, both in univariate and multivariate analyses. In a previous study from our group, TYMS genotypes were associated with TTP only in patients treated with 5FU plus oxaliplatin but not in those treated with capecitabine plus oxaliplatin (Martinez-Balibrea et al, 2008). Carlini et al (2005) also evaluated the relationship between TYMS polymorphisms and response to capecitabine plus irinotecan in metastatic CRC patients, but no significant association was noted. On the basis of these data, we proposed that TYMS genotype might be useful to predict response to 5FU-based schedules.

Taking into account these results, we propose a possible genetic algorithm to select first-line treatment in metastatic CRC patients (Figure 4). First, due to a lack of response, those patients with TYMS genotypes 2TRP/3TRP or 3TRP/3TRP should not receive irinotecan+5FU; second, patients within TYMS 2TRP/2TRP with genotype UGT1A1*28/*28 or UGT1A7*3/*3 or UGT1A9*1/*1 should receive an adjusted dose of irinotecan and be under a stricter surveillance, as they are prone to a higher risk of severe toxicity. In contrast, these patients are more likely to respond and survive longer.

Figure 4
Figure 4

Genetic-based algorithm for first-line treatment selection in colorectal cancer patients. An X in a genotype represents any of the possible alleles. A given patient would be first genotyped for TYMS. If he were heterozygous or homozygous for the 3TRP allele, he would receive an oxaliplatin-based regimen. If he was not, he would be then genotyped for UGT1A1*28. If genotype was UGT1A1*28/*28, this patient would receive a low dose of irinotecan, otherwise he would be genotyped for UGT1A7*3. If he were homozygous for the UGT1A7*3 allele, he would receive a low dose of irinotecan. Genotypes different from UGT1A7*3/*3 would be then analysed for UGT1A9*22. If the resulting genotype was UGT1A9*1/*1, this patient would receive a low dose of irinotecan, otherwise he would receive a standard irinotecan plus 5FU schedule.

This study is limited by its retrospective design and requires further confirmation in independent studies. If so, our findings might be of clinical value and would help clinicians to better select first-line treatment in advanced CRC patients.

Change history

  • 29 March 2012


  1. , , , , , , , , , , , , , (2009) Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) vs biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Ann Oncol 20: 251–257

  2. , , , , , , , , , (2009) Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 27: 5519–5528

  3. , , , , , , , , (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11: 1226–1236

  4. , , , , , , , (2009) Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27: 2457–2465

  5. , , , (1999) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 260: 199–202

  6. , , , , , , , , , (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13: 3269–3275

  7. , , , , , , , , , , , , (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041–1047

  8. , , , , , , , , , , , , , , , (2002) Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20: 2832–2843

  9. , , , , , (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62: 608–617

  10. , , , , (2000) Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10: 629–644

  11. , , , , , , , , (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24: 2237–2244

  12. , , , , (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99: 1290–1295

  13. , , , (2001) A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85: 827–830

  14. , , , , , , , , , (2009) Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27: 2604–2614

  15. , , , , , , , , , , , (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22: 1382–1388

  16. , , , , , (2002) Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 22: 2805–2809

  17. , , , , , , , (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65: 576–582

  18. , , , , , , , (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847–854

  19. , , , , , , , , (2001) Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7: 4096–4101

  20. , , , , (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187–4191

  21. , , , , , , , (2005) Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol 67: 1732–1739

  22. , , , , , , , , , (2008) UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 112: 1932–1940

  23. , , , , , , , , , , , , , , (2008) Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics 18: 161–168

  24. , , , , , , , (2004) A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14: 319–327

  25. , , , , , (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91: 678–682

  26. (2005) Thymidylate synthase pharmacogenetics. Invest New Drugs 23: 533–537

  27. , , , , , , , , , , , , (2008) Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 44: 1229–1237

  28. , , , , (1996) Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347: 578–581

  29. , (2008) Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 13: 1074–1083

  30. , , , , , , , , , (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1: 65–70

  31. , , , , , (2004) Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10: 5151–5159

  32. , , , , , , , , , , , , , , , , , , , , , (2008) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 8: 278–288

  33. , , , , , , , , (2003) Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Cancer Res 9: 4983–4991

  34. , , , , (1994) Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 34(Suppl): S53–S57

  35. , , , , (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22: 1928–1929

Download references

Author information

Author notes

    • M Navarro

    Current address: Cancer Control and Prevention Service, Institut Català d'Oncologia, Hospital Duran i Reynals, Avda. Gran Vía s/n Km 2.7, L'Hospitalet de Llobregat 08907, Spain

    • A Carrato

    Current address: Medical Oncology Service, Ramon y Cajal University Hospital, Ctra. De Colmenar Viejo Km 9,100, Madrid 28049, Spain


  1. Medical Oncology Service, Institut Català d'Oncologia, Hospital Germans Trias I Pujol. C/Ctra. Canyet s/n, Badalona 08916, Spain

    • E Martinez-Balibrea
    • , A Abad
    • , L Layos
    •  & J L Manzano
  2. Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (FIGTP). C/Ctra. De Can Ruti, camí de les escoles s/n, Badalona 08916, Spain

    • E Martinez-Balibrea
    • , A Abad
    • , A Martínez-Cardús
    •  & A Ginés
  3. Medical Oncology Service, Complejo Hospitalario Universitario Juan Canalejo, C/Lugar Xubias De Arriba 84, A Coruña 15006, Spain

    • M Valladares
  4. Medical Oncology Service, Institut Català d'Oncologia, Hospital Duran I Reynals, Avda. Gran Vía s/n Km 2.7, L'Hospitalet de Llobregat 08907, Spain

    • M Navarro
  5. Medical Oncology Service, Hospital Universitario Reina Sofía, C/Menéndez Pidal s/n, Córdoba 14004, Spain

    • E Aranda
  6. Medical Oncology Service, Hospital de la Santa Creu I Sant Pau, C/Sant Antoni Maria Claret, 167, Barcelona 08025, Spain

    • E Marcuello
  7. Medical Oncology Service, Hospital Carlos Haya, Avda. Carlos Haya s/n, Málaga 29010, Spain

    • M Benavides
  8. Medical Oncology Service, Hospital General Universitario de Alicante, Avda. Pintor Baeza s/n, Alicante 03010, Spain

    • B Massutí
  9. Medical Oncology Service, Hospital General Universitario de Elche, Camí Almassera 11, Elche 03203, Spain

    • A Carrato
  10. Biostatistics and Bioinformatics Unit, Institut Català d'Oncologia, Hospital Duran i Reynals, Avda. Gran Vía s/n Km 2.7, L'Hospitalet de Llobregat 08907, Spain

    • M Navarro
    •  & V Moreno
  11. Institut d'Investigació de Bellvitge, Feixa Llarga s/n, L'Hospitalet de Llobregat 08907, Spain

    • V Moreno
  12. Department of Clinical Sciences, University of Barcelona, Feixa Llarga s/n, L'Hospitalet de Llobregat 08907, Spain

    • V Moreno


  1. Search for E Martinez-Balibrea in:

  2. Search for A Abad in:

  3. Search for A Martínez-Cardús in:

  4. Search for A Ginés in:

  5. Search for M Valladares in:

  6. Search for M Navarro in:

  7. Search for E Aranda in:

  8. Search for E Marcuello in:

  9. Search for M Benavides in:

  10. Search for B Massutí in:

  11. Search for A Carrato in:

  12. Search for L Layos in:

  13. Search for J L Manzano in:

  14. Search for V Moreno in:

Corresponding author

Correspondence to A Abad.

Supplementary information

Word documents

  1. 1.

    Supplementary Table S1

About this article

Publication history






Supplementary Information accompanies the paper on British Journal of Cancer website (

Further reading